Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
October 2024 - At the Partnership Opportunities in Drug Delivery (PODD) conference, Robert Hidalgo showcased Portal Instrument's latest advancements on its reusable, electro-mechanical drug delivery platform.
Boston, MA – October 27, 2024– Portal Instruments, a leader in innovative drug delivery technology, presented its latest advancements in its drug delivery injection systems at the Partnership Opportunities in Drug Delivery (PODD) conference. Robert Hidalgo, VP of Operations, delivered a presentation highlighting the transformative potential of the company’s technology to revolutionize the patient experience.
PODD, a premier event for the pharmaceutical and drug delivery industries, provided an ideal platform for Portal Instruments to showcase its cutting-edge technology to key stakeholders and potential partners. Hidalgo’s presentation emphasized the significant challenges associated with traditional needle-based injections, including viscosity challenges, patient anxiety and environmental waste. Portal’s platform offers a compelling solution, aiming to eliminate these issues and significantly enhance the patient experience.
"Our electro-mechanical platform is designed to address the significant unmet needs in injectable drug delivery and solve the challenges of delivering high viscosity drugs while also taking care of the patient and the planet," said Robert Hidalgo
The PODD conference offered a valuable opportunity for Portal Instruments to connect with potential partners in the pharmaceutical and biotech sectors.
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
Please fill out the details below and we will get back to you shortly.